31.07.2018 • News

AstraZeneca sells Atacand Rights

Anglo-Swedish drugmaker AstraZeneca has agreed to sell commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Germany’s Cheplapharm Arzneimittel. Both prescription medicines are recommended for treatment of heart failure and hypertension.

Mark Mallon, executive vice president, Global Product & Portfolio Strategy at AstraZeneca, said the agreement forms part of the company’s strategy of streamlining its portfolio of mature medicines to enable reinvestment in its main therapy areas while at the same time bringing new medicines to patients. Cheplapharm’s strong European presence will help expand the commercial potential of Atacand, Mallon added.

The transaction is expected to be completed in the third quarter. AstraZeneca said it will continue to manufacture and supply Atacand and Atacand Plus under an agreement with Cheplapharm and will continue to commercialize the medicines in all markets where it still holds the rights.

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Free Virtual Event

CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.